Scinai Immunotherapeutics Ltd. (SCNI)
Market: NASD |
Currency: USD
Address: Jerusalem BioPark
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
📈 Scinai Immunotherapeutics Ltd. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
100-200%
-
Net Income Growth Range (1Y):
100-200%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2024 |
- |
$0.100000 |
- |
2024-05-21 |
- |
Stock split |
|
Total Amount for 2024: $0.100000 |
| 2022 |
- |
$0.100000 |
- |
2022-11-25 |
- |
Stock split |
|
Total Amount for 2022: $0.100000 |
📅 Earnings & EPS History for Scinai Immunotherapeutics Ltd.
| Date | Reported EPS |
|---|
| 2025-05-07 | - |
| 2024-11-25 | - |
| 2024-08-15 | - |
| 2024-08-14 | - |
| 2024-07-02 | - |
| 2024-07-01 | - |
| 2024-05-15 | -0.47 |
| 2024-05-14 | -0.47 |
| 2023-10-31 | 0.8 |
| 2023-10-30 | 0.8 |
| 2023-08-11 | -1.11 |
| 2023-08-10 | -1.11 |
📰 Related News & Research
No related articles found for "scinai immunotherapeutics".
